These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 20181452)

  • 1. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
    Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
    Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Reilly LM; Gerami P; Guitart J
    Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
    Imarisio I; Paglino C; Ganini C; Magnani L; Caccialanza R; Porta C
    Future Oncol; 2012 Aug; 8(8):1051-7. PubMed ID: 22894676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
    Sibaud V; Delord JP; Chevreau C
    Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sorafenib(Nexavar)].
    Miyanaga N; Akaza H
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
    Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib.
    Rini BI
    Expert Opin Pharmacother; 2006 Mar; 7(4):453-61. PubMed ID: 16503817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Speeding up cancer-drug development.
    Burton A
    Lancet Oncol; 2006 Oct; 7(10):798. PubMed ID: 17039633
    [No Abstract]   [Full Text] [Related]  

  • 12. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hand-foot syndrome and sorafenib].
    Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
    Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G; Paggi S
    N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe sorafenib-induced hand-foot skin reaction.
    Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
    Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.